Edwards Lifesciences Co. (NYSE:EW) Stock Position Increased by Inspire Investing LLC

Inspire Investing LLC grew its position in Edwards Lifesciences Co. (NYSE:EW) by 40.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 14,242 shares of the medical research company’s stock after buying an additional 4,096 shares during the period. Inspire Investing LLC’s holdings in Edwards Lifesciences were worth $1,054,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in EW. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter worth about $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Peoples Bank KS acquired a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $40,000. Finally, JFS Wealth Advisors LLC raised its holdings in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,000 shares of company stock valued at $2,195,180. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on EW. The Goldman Sachs Group lifted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price on the stock. in a report on Thursday, January 16th. Piper Sandler dropped their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Morgan Stanley restated an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Finally, Robert W. Baird dropped their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Stock Performance

Shares of EW opened at $68.95 on Friday. The company has a market capitalization of $40.66 billion, a PE ratio of 9.95, a PEG ratio of 3.59 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company’s 50 day moving average price is $72.25 and its 200 day moving average price is $70.86. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the company posted $0.59 EPS. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. Research analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.